Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

LifeStance Health (LFST) EBITDA (2020 - 2025)

LifeStance Health (LFST) has disclosed EBITDA for 6 consecutive years, with $11.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 267.79% to $11.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.7 million, a 114.85% increase, with the full-year FY2025 number at $8.7 million, up 114.85% from a year prior.
  • EBITDA was $11.7 million for Q4 2025 at LifeStance Health, up from $732000.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $11.7 million in Q4 2025 to a low of -$290.9 million in Q4 2021.
  • A 5-year average of -$47.0 million and a median of -$35.1 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 3556.71% in 2021, then skyrocketed 267.79% in 2025.
  • LifeStance Health's EBITDA stood at -$290.9 million in 2021, then skyrocketed by 83.99% to -$46.6 million in 2022, then dropped by 1.01% to -$47.0 million in 2023, then soared by 85.22% to -$7.0 million in 2024, then surged by 267.79% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for LFST's EBITDA are $11.7 million (Q4 2025), $732000.0 (Q3 2025), and -$4.1 million (Q2 2025).